Tivanisiran is an innovative small interfering RNA (siRNA) therapeutic agent developed by Sylentis, a Spanish biopharmaceutical company specializing in RNAi technology.

Eisai showcases new clinical results indicating that the anti-MTBR tau antibody E2814 may block tau propagation at the 17th CTAD conference on Alzheimer's clinical trials.

Laroprovstat(AZD-0780) is a small molecule drug developed by AstraZeneca PLC, targeting the PCSK9 protein.

Bitterroot Bio has confirmed the conclusion of participant enrollment for its Phase 1 trial assessing BRB-002 in healthy subjects.

Fitusiran is an investigational RNA interference (RNAi) therapeutic developed by Alnylam Pharmaceuticals in collaboration with Sanofi Genzyme.

GSK has struck a deal to buy CMG1A46 from Chimagen Biosciences to enhance its immunology portfolio.

LRallybio has received approval for clinical trial applications to conduct a Phase 2 study of RLYB212 in expectant mothers who are at increased risk of alloimmunization and FNAIT.

Immunome reveals strong preclinical results showcasing significant anti-tumor effects of IM-1021.

Aro Biotherapeutics has begun recruiting participants for a Phase 1b study of ABX1100 in individuals with Late-Onset Pompe Disease (LOPD).

Clover reveals encouraging clinical results for its RSV vaccine SCB-1019 when compared to GSK’s AREXVY.

According to statistical data, the miRNA drug market was estimated at approximately $160.5 million in 2017, with an expected compound annual growth rate (CAGR) of 18.6%.

Monte Rosa Therapeutics has signed a worldwide licensing deal with Novartis to promote VAV1-targeted molecular glue degraders that modulate T and B cells.